BiotechTube
Tian Medical

Tian Medical

San Francisco, United States· Est.
tianmedical.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Tian Medical is a private medical device company commercializing the Tx360® Nasal Applicator, a patented, FDA-cleared device for targeted drug delivery to the sphenopalatine ganglion (SPG). Founded by interventional pain specialist Dr. Tian Xia, the company aims to modernize established SPG block procedures for conditions like cluster headaches and migraines. The device is already revenue-generating, distributed to hundreds of providers and institutions in the US, Canada, and Europe. Tian Medical operates at the intersection of medical devices and localized drug delivery, seeking to improve efficacy and reduce systemic medication exposure.

Pain ManagementHeadache DisordersNeurology

Technology Platform

Patented intranasal applicator for precise, trans-mucosal drug delivery to the sphenopalatine ganglion (SPG) nerves.

Opportunities

Large and growing global market for headache and facial pain disorders creates significant demand for effective, minimally invasive treatments.
The shift towards interventional procedures in pain management and the need to standardize SPG blocks present a clear opportunity for a dedicated device.
Geographic expansion and potential exploration of new drug formulations for delivery via the Tx360 platform offer avenues for growth.

Risk Factors

Commercial success depends on convincing clinicians to adopt a dedicated device over traditional, lower-cost methods, requiring strong clinical and economic evidence.
Reimbursement challenges and competition from both alternative procedural tools and advancing pharmaceutical therapies pose significant market risks.
The company faces concentration risk with a single commercial product.

Competitive Landscape

Competition includes traditional, non-standardized methods for SPG blocks (e.g., cotton-tipped applicators, simple catheters) and alternative neuromodulation devices for headache. The primary competitive challenge is displacing entrenched, low-tech habits rather than competing against other dedicated devices, though new entrants could emerge. The company also competes indirectly with the broader pharmaceutical market for migraine and pain therapeutics.

More companies in Drug Delivery & Formulation →More companies in United States →